Literature DB >> 7685389

The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa.

G Hale1, P D Rye, A Warford, I Lauder, A Brito-Babapulle.   

Abstract

The CAMPATH-1 (CDw52) antigen is a small glycosylphosphatidylinositol (GPI) anchored glycoprotein with a mature peptide comprising only 12 amino acids. It is abundantly expressed on human lymphocytes and is an unusually good target for complement-mediated cell lysis. The immunosuppressive and lymphocyte-depleting effects of CAMPATH-1 antibodies are being tested in a variety of diseases. Here we show that the antigen is also expressed at a high level in the male reproductive system, being found in the epididymis, seminal vesicle, seminal plasma and on the surface of mature (but not testicular) spermatozoa. Its possible transfer from epithelial cells in the epididymis to maturing sperm may represent a novel method of acquisition of cell surface antigens. In the presence of human complement, CAMPATH-1 antibodies inhibited the motility of washed sperm. However, seminal plasma blocks antibody binding and can protect sperm from this cytotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685389     DOI: 10.1016/0165-0378(93)90007-5

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  15 in total

Review 1.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

2.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

3.  Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

Authors:  J R Salisbury; N T Rapson; J D Codd; M V Rogers; A B Nethersell
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

4.  Successful fertility restoration after allogeneic hematopoietic stem cell transplantation.

Authors:  Helen Gharwan; Nicola M Neary; Mary Link; Matthew M Hsieh; Courtney D Fitzhugh; Richard J Sherins; John F Tisdale
Journal:  Endocr Pract       Date:  2014-09       Impact factor: 3.443

5.  GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells.

Authors:  I A Rooney; J E Heuser; J P Atkinson
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

Review 6.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

7.  The immune-related gene CD52 is a favorable biomarker for breast cancer prognosis.

Authors:  Yan-Fei Ma; Yongcheng Chen; Dalang Fang; Qianfang Huang; Zhizhai Luo; Qiang Qin; Jiayao Lin; Caihua Zou; Minyu Huang; Dongdong Meng; Qun Huang; Guan-Ming Lu
Journal:  Gland Surg       Date:  2021-02

8.  Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Authors:  Sambasiva P Rao; Jose Sancho; Juanita Campos-Rivera; Paula M Boutin; Peter B Severy; Timothy Weeden; Srinivas Shankara; Bruce L Roberts; Johanne M Kaplan
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

Review 9.  Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.

Authors:  Divyanshu Dubey; Christopher A Cano; Olaf Stuve
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-18       Impact factor: 2.570

10.  Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G.

Authors:  Robert A Eagle; Gillian Flack; Anthony Warford; Jesús Martínez-Borra; Insiya Jafferji; James A Traherne; Maki Ohashi; Louise H Boyle; Alexander D Barrow; Sophie Caillat-Zucman; Neil T Young; John Trowsdale
Journal:  PLoS One       Date:  2009-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.